In development: Guidance, quality standards and advice
Showing 426 to 430 of 430
| Title | Type | Expected publication date |
|---|---|---|
| Zanidatamab for treating HER2-positive advanced biliary tract cancer after 1 or more systemic treatments [ID6388] | Technology appraisal guidance | |
| Zanubrutinib for untreated chronic lymphocytic leukaemia [ID5079] | Technology appraisal guidance | TBC |
| Zilucoplan for treating antibody positive generalised myasthenia gravis [ID4008] | Technology appraisal guidance | TBC |
| Zio XT for detecting cardiac arrhythmias | Medical technologies guidance | TBC |
| Zuranolone for treating postnatal depression [ID6431] | Technology appraisal guidance | TBC |